Chernenko O. V.

RELATIONSHIP BETWEEN THYROID STIMULATING HORMONE AND THYROID CANCER


About the author:

Chernenko O. V.

Heading:

LITERATURE REVIEWS

Type of article:

Scentific article

Annotation:

To date, there is growing number of well-known predictors of malignancy of the thyroid nodules including a solid fixed formation that is detected by physiological examination, rapid growth and large size of the site, tracheostomy, dysphagia or lymphadenopathy, irradiation in the history of low doses of radiation of the head and neck in infancy, age less for 20 years and more than 70 years and male gender. Detection of thyroid tumors, characterized by benign course and favorable prognosis, can significantly reduce the number of surgical interventions. However, there are cases where the potential of malignancy of the tumor can not be determined. In this case, alternative diagnostic methods are required. These may include the detection of BRAF and RAS spot mutations, PAX8 / PPARγ and RET / PTC translocation, but given the high cost of research data and relatively low sensitivity, these methods are not always suitable for routine diagnostics. The determination of the level of serum hormones may be cheaper and faster. This review is devoted to the assessment of the current concept on thyroid stimulating hormone role in development and progression differentiated thyroid cancer, namely papillary thyroid carcinoma. Numerous studies demonstrated the significance of high (TSH) in thyroid nodes malignisation and progression associated with rapid growth, aggressiveness and metastasis development. Many authors find this test useful for distinguishing benign and malignant thyroid tumors and suggest that it may be used as an auxiliary in the diagnostics. However there some authors who did not find any relationship between TSH and thyroid cancer. Finally, there is a growing body of investigations demonstrating the opposite relations between TSH levels and thyroid malignancies. Genetic studies also are in favor of the reciprocal association between the level of TSH and the development of thyroid cancer. Such controversy could be related with different sampling and design of study as well as with confounding factors including patients age, benign thyroid nodules with autonomy and autoimmune thyroiditis.

Tags:

thyroid cancer, thyroid stimulating hormone

Bibliography:

  1. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102-32. DOI: 10.1210/er.2002-0016
  2. Liu FC, Lin HT, Lin SF, Kuo CF, Chung TT, Yu HP. Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. Oncotarget. 2017;8(45):78429-51. DOI: 10.18632/oncotarget.19488
  3. Shi LL, DeSantis C, Jemal A, Chen AY. Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. Laryngoscope. 2017;127(10):2437-41. DOI: 10.1002/lary.26473
  4. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. DOI: 10.1089/thy.2015.0020
  5. Hyeong SA, Hyun JK, Kyoung HK, Lee YS, Han SJ, Kim Y, et al. Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality. Тhyroid, 2016;26(11):1535-40. DOI: 10.1089/thy.2016.0075
  6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69-90. DOI: 10.3322/caac.20107
  7. Amendoeira I, Maia T, Sobrinho-Simões M. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Relat Cancer. 2018;25(4):R247-R58. DOI: 10.1530/ERC-17-0513
  8. Sulaieva O, Belemets N, Selezniov O, Chuba VYa, Shapochka DA, Chernenko EV. Histological and molecular diagnostics of thyroid tumors in line with international guidelines and recommendations. Clin Endocrinol. Endocr. Surg. 2018;1(61):7-14. DOI: https://doi.org/10.24026/18181384.1(61).2018.126898
  9. Thompson LD. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol. 2016;29(7):698-707. DOI: 10.1038/ modpathol.2016.65
  10. Lin JD, Hsueh C, Huang BY. Papillary thyroid carcinoma with different histological patterns. Chang Gung Med. J. 2011;34(1):23-34.
  11. Nabhan F, Ringel MD. Thyroid nodules and cancer management guidelines: comparisons and controversies. Endocr. Relat. Cancer. 2017;24(2):R13-R26. DOI: 10.1530/ERC-16-0432
  12. 8th Edition AJCC Cancer Staging Manual. Available from: https://cancerstaging.org/CSE/general/Pages/articles.aspx
  13. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. DOI: 10.1089/thy.2015.0020
  14. Ying W, Xinrong Zh, Siyue L. Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules. PLoS One. 2016;11(9). DOI: 10.1371/ journal.pone.0163039
  15. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-7. DOI: 10.1210/jc.2011-1469
  16. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):105869. DOI: 10.1016/S0140-6736(13)60109-9
  17. Golbert L, Cristo AP, Faccin CS. Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study. PLoS One. 2017;12(11):e0188123. DOI: 10.1371/journal.pone.0188123
  18. Spencer CA. Thyroid function tests: assay of thyroid hormones and related substances. Thyroid Disease Manager. 2017. Available from: http:// www.thyroidmanager.org/chapter/assay-of-thyroid-hormones-and-related-substances3/
  19. Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed – a review for primary care. Clin Med Res. 2016;14:83-92. DOI: 10.3389/fendo.2016.00142
  20. Pearce SHS, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2:215-28. DOI: 10.1159/000356507
  21. Boelaert K, Horacek J, HolderRL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. Journal of Clinical Endocrinology and Metabolism. 2006;91(11):4295-301. DOI: 10.1210/jc.2006-0527
  22. Haymart MR, Repplinger DJ, Leverson GE. Higher serum TSH level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2007;93:809-14. DOI: 10.1210/jc.2007-2215
  23. Duccini K, Souza M, Delfim R. High Serum Thyrotropin Concentrations Within the Reference Range: A Predictor of Malignancy in Nodular Thyroid Disease. Med Princ Pract. 2018;27(3):272-7. DOI: 10.1159/000488196
  24. Yazici P, Mihmanli M, Bozkurt E, Ozturk FY, Uludag M. Which is the best predictor of thyroid cancer: thyrotropin, thyroglobulin or their ratio? Hormones (Athens). 2016;15(2):256-63. DOI: 10.14310/horm.2002.1677
  25. Rinaldi S. Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study. JNCI: J Nat Cancer Institute. 2014;106(6):2014.
  26. Sulem GP, Gudbjartsson D, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet. 2012;44(3):319-22. DOI: 10.1038/ng.1046
  27. Derwahl M, Broecker M. Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab. 1999;84:829-34. DOI: 10.1210/jc.2007-2215
  28. Mazzaferri EL. 2000 Thyroid cancer and Graves’ disease: the controversy ten years later. Endocrine Practice. 2000;6:221-5. DOI: 10.1210/ jc.2007-2215
  29. Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. A.M.A. Archives of Surgery. 1955;70:291-7. DOI: 10.1001/archsurg.1955.01270080137023

Publication of the article:

«Bulletin of problems biology and medicine» Issue 4 Part 2 (147), 2018 year, 84-88 pages, index UDK 616.018.72:616.441-006.6-037

DOI: